US EditionPublished • loading... • Updated
Haitham Amal: targeting autism spectrum disorder, Alzheimer’s disease, and glioblastoma with small-molecule drugs
Summary by Advanced Science News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Haitham Amal: targeting autism spectrum disorder, Alzheimer’s disease, and glioblastoma with small-molecule drugs
With FDA orphan drug approval secured, Amal and his team are preparing for phase 1 clinical trials of their small-molecule drugs in 2026. The post Haitham Amal: targeting autism spectrum disorder, Alzheimer’s disease, and glioblastoma with small-molecule drugs appeared first on Advanced Science News.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
